Following the investigation into the role of DHODH inhibition on p53, we then conducted cell viability assays to examine the effect of supplementation on melanoma cell growth using a sulforhodamine B viability (SRB) assay (Figs. 4C and 5 and Fig. S3). This evidence concerns the gene TP53 and melanoma.